These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Schuurs-Hoeijmakers syndrome in two patients from Japan. Hoshino Y; Enokizono T; Imagawa K; Tanaka R; Suzuki H; Fukushima H; Arai J; Sumazaki R; Uehara T; Takenouchi T; Kosaki K Am J Med Genet A; 2019 Mar; 179(3):341-343. PubMed ID: 30588754 [TBL] [Abstract][Full Text] [Related]
3. Prenatal and postnatal diagnosis of Schuurs-Hoeijmakers syndrome: Case series and review of the literature. Seto MT; Bertoli-Avella AM; Cheung KW; Chan KY; Yeung KS; Fung JL; Beetz C; Bauer P; Luk HM; Lo IF; Lee CP; Chung BH; Kan AS Am J Med Genet A; 2021 Feb; 185(2):384-389. PubMed ID: 33166031 [TBL] [Abstract][Full Text] [Related]
4. Genetic characterization of Schuurs-Hoeijmakers syndrome in a moroccan individual with heterozygote PACS1 mutation. Abbassi M; Bourmtane A; Sayel H; El Mouhi H; Jalte M; Elasri YA; Askander O; El Fahime E; Bouguenouch L Mol Biol Rep; 2023 Nov; 50(11):9121-9128. PubMed ID: 37747683 [TBL] [Abstract][Full Text] [Related]
5. Acquisition of an oncogenic fusion protein serves as an initial driving mutation by inducing aneuploidy and overriding proliferative defects. Loupe JM; Miller PJ; Bonner BP; Maggi EC; Vijayaraghavan J; Zabaleta J; Taylor CM; Tsien F; Crabtree JS; Hollenbach AD Oncotarget; 2016 Sep; 7(39):62814-62835. PubMed ID: 27588498 [TBL] [Abstract][Full Text] [Related]
6. Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements. Vicente-García C; Villarejo-Balcells B; Irastorza-Azcárate I; Naranjo S; Acemel RD; Tena JJ; Rigby PWJ; Devos DP; Gómez-Skarmeta JL; Carvajal JJ Genome Biol; 2017 Jun; 18(1):106. PubMed ID: 28615069 [TBL] [Abstract][Full Text] [Related]
7. PAX3-FOXO1: Zooming in on an "undruggable" target. Wachtel M; Schäfer BW Semin Cancer Biol; 2018 Jun; 50():115-123. PubMed ID: 29146205 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of PAX3/7-FOXO1 fusion status in alveolar rhabdomyosarcoma: Systematic review and meta-analysis. Kubo T; Shimose S; Fujimori J; Furuta T; Ochi M Crit Rev Oncol Hematol; 2015 Oct; 96(1):46-53. PubMed ID: 26008753 [TBL] [Abstract][Full Text] [Related]
9. Loss of MST/Hippo Signaling in a Genetically Engineered Mouse Model of Fusion-Positive Rhabdomyosarcoma Accelerates Tumorigenesis. Oristian KM; Crose LES; Kuprasertkul N; Bentley RC; Lin YT; Williams N; Kirsch DG; Linardic CM Cancer Res; 2018 Oct; 78(19):5513-5520. PubMed ID: 30093562 [TBL] [Abstract][Full Text] [Related]
10. Regulation of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Ahn EH Anticancer Res; 2013 May; 33(5):2029-35. PubMed ID: 23645752 [TBL] [Abstract][Full Text] [Related]
11. A Novel PACS1 Variant Associated With Schuurs-Hoeijmakers Syndrome Phenotype in an Indigenous Descendant in Brazil: A Case Report. Lucena PH; Nonaka C; Armani-Franceschi G; Carneiro P; Sales H; Lucena M; Bandeira ID; Solano B; Lucena R Cureus; 2022 Oct; 14(10):e30486. PubMed ID: 36415352 [TBL] [Abstract][Full Text] [Related]
12. PAX3-NCOA1 alveolar rhabdomyosarcoma of the tongue: A rare entity with challenging diagnosis and management. Di Carlo D; Chargari C; Scoazec JY; Cotteret S; Felix A; Moalla S; Temam S; Minard-Colin V Pediatr Blood Cancer; 2021 Nov; 68(11):e29288. PubMed ID: 34424607 [TBL] [Abstract][Full Text] [Related]
15. Schuurs-Hoeijmakers syndrome in a patient from India. Dutta AK Am J Med Genet A; 2019 Apr; 179(4):522-524. PubMed ID: 30690871 [TBL] [Abstract][Full Text] [Related]
16. Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma. Xie Z; Babiceanu M; Kumar S; Jia Y; Qin F; Barr FG; Li H Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13126-13131. PubMed ID: 27799565 [TBL] [Abstract][Full Text] [Related]
17. Triple diagnosis of Wiedemann-Steiner, Waardenburg and DLG3-related intellectual disability association found by WES: A case report. Matis T; Michaud V; Van-Gils J; Raclet V; Plaisant C; Fergelot P; Lasseaux E; Arveiler B; Trimouille A J Gene Med; 2020 Aug; 22(8):e3197. PubMed ID: 32246869 [TBL] [Abstract][Full Text] [Related]
18. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma. Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962 [TBL] [Abstract][Full Text] [Related]
19. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]